VMAT2 Loss in Striatum of Long COVID and Relevance to ME/CFS
1 Liu et al. 2026 — Primary VMAT2 PET Study in Long COVID
Full Citation:: Liu YK, Persaud D, Vieira EL, et al. Loss of vesicular monoamine transporter 2 in striatum of long COVID and relationship to neuropsychiatric symptoms. eBioMedicine. 2026. (Liu et al. 2026) DOI:: 10.1016/j.ebiom.2026.106339 Study Design:: Case-control PET imaging study Sample Size:: n=24 long COVID, n=24 age-matched healthy controls (extended to 43) Key Findings::
- (+)[11C]DTBZ BPND (VMAT2) reduced 16-20% in ventral striatum, dorsal putamen, dorsal caudate (P=4×10⁻⁵)
- COVID-recovered controls had normal VMAT2 binding vs never-COVID controls (P=0.77)
- Apathy severity correlated with ventral striatum VMAT2 (r=−0.54, P=0.0069)
- Motor slowing (Finger Tapping) correlated with dorsal putamen VMAT2 (r=0.51, P=0.010)
- Memory decline correlated with dorsal caudate VMAT2 (r=0.58, P=0.0029)
- No relationship to BDI depression score or peripheral DA metabolite markersConclusion:: Long COVID involves reduced striatal dopaminergic terminal integrity, suggesting DA augmentation (L-dopa, MAOIs) as treatment direction Limitations:: Young sample (mean 32.2); apathy-predominant phenotype; n=24; no pre-COVID baseline; no D2/D3 receptor measure ME/CFS Relevance:: First direct evidence of dopaminergic terminal loss in a postviral chronic illness. If replicated in ME/CFS, would establish DA deficiency as treatment target. Circumstantial support: overlapping symptoms (apathy, cognitive/motor slowing), shared postviral aetiology, and striatal gliosis in ME/CFS (Nakatomi 2014) convergent with Toronto cohort findings. Certainty Assessment::
- *Quality:* High (eBioMedicine; well-validated PET methodology; recovery control group)
- *Sample:* Medium (n=24 per group; limited power for subgroup analyses)
- *Replication:* First study of its kind — requires independent replication
- *Score:* 0.722 Braga et al. 2023 — Striatal Neuroinflammation in Long COVID (Same Cohort)
Full Citation:: Braga J, Lepra M, Kish SJ, et al. Neuroinflammation After COVID-19 With Persistent Depressive and Cognitive Symptoms. JAMA Psychiatry. 2023;80(8):787–795. (Braga et al. 2023) DOI:: 10.1001/jamapsychiatry.2023.1321 PMID:: 37256580 Study Design:: Cross-sectional TSPO PET [18F]-FEPPA imaging Sample Size:: n=20 COVID-DC, n=20 healthy controls Key Findings::
- Elevated TSPO binding (microglial activation) in striatum, prefrontal cortex, ACC
- TSPO binding correlated with depressive symptom severity
- Same CAMH Toronto cohort subsequently studied for VMAT2 (Liu 2026)Conclusion:: Persistent neuroinflammation (gliosis) is present in long COVID striatum ME/CFS Relevance:: Provides upstream mechanism for VMAT2 loss: gliosis → synaptic pruning/ROS → DA terminal damage. Striatal gliosis also reported in ME/CFS (Nakatomi 2014). Certainty Assessment::
- *Quality:* High (JAMA Psychiatry; well-validated tracer)
- *Sample:* Medium (n=20 per group)
- *Replication:* Partially replicated by Visser 2025 (variable) and VanElzakker 2024 (vascular-linked)
- *Score:* 0.723 Braga et al. 2025 — Astrogliosis in Long COVID Striatum
Full Citation:: Braga J, Kuik EJY, Lepra M, et al. Astrogliosis marker [11C]SL25.1188 after COVID-19 with ongoing depressive and cognitive symptoms. Biological Psychiatry. 2025;97(8):816–824. (Braga et al. 2025) DOI:: 10.1016/j.biopsych.2024.09.027 PMID:: 39395470 Study Design:: Cross-sectional PET [11C]SL25.1188 (MAO-B, astrogliosis) Sample Size:: n=21 COVID-DC, n=22 controls Key Findings::
- Elevated MAO-B binding (astrogliosis) in striatum, PFC, ACC, insula
- Astrogliosis in identical striatal regions showing VMAT2 loss in Liu 2026
- MAO-B hyperactivity may directly degrade dopamine (additional mechanism)Conclusion:: Dual microglial (TSPO) and astroglial (MAO-B) activation in long COVID striatum ME/CFS Relevance:: MAO-B hyperactivity as treatment target (MAO inhibitors). Astrogliosis also reported in ME/CFS neuropathology. Certainty Assessment::
- *Quality:* High (Biological Psychiatry; same well-characterized cohort)
- *Sample:* Medium (n=21 per group)
- *Replication:* Consistent with Braga 2023; extends to astroglial compartment
- *Score:* 0.704 Visser et al. 2025 — Heterogeneous TSPO in Post-COVID Fatigue
Full Citation:: Visser D, Golla SSV, Palard-Novello X, et al. Varying levels of inflammatory activity in brain and body of patients with persistent fatigue and difficulty concentrating after COVID-19: a TSPO PET study. Journal of Nuclear Medicine. 2025;66(11):1787–1794. (Visser et al. 2025) DOI:: 10.2967/jnumed.124.269297 Sample Size:: n=27 post-COVID fatigue, n=18 controls Key Findings:: Variable TSPO binding — subset increased, subset decreased — highlighting neuroinflammatory heterogeneity in long COVID ME/CFS Relevance:: Neuroinflammatory heterogeneity likely also present in ME/CFS, complicating interpretation of Raijmakers 2022 null finding. Certainty Assessment:: - Quality: Medium-high - Sample: Moderate (n=27) - Replication: Partially consistent with Braga 2023 - Score: 0.55
5 VanElzakker et al. 2024 — Vascular-Linked TSPO in PASC
Full Citation:: VanElzakker MB, Bues HF, Brusaferri L, et al. Neuroinflammation in post-acute sequelae of COVID-19 (PASC) as assessed by [11C]PBR28 PET correlates with vascular disease measures. Brain, Behavior, and Immunity. 2024;119:713–723. (VanElzakker et al. 2024) DOI:: 10.1016/j.bbi.2024.04.015 Key Findings:: TSPO binding correlated with vascular disease measures, not uniform neuroinflammation. Raises alternative source of TSPO signal in long COVID. ME/CFS Relevance:: Important to consider vascular component of TSPO signal in both long COVID and ME/CFS. Not all TSPO increase = gliosis. Certainty Assessment:: - Quality: Medium - Sample: Small (n=12) - Replication: Single study - Score: 0.58
6 Yang et al. 2024 — DA Neuron Senescence by SARS-CoV-2
Full Citation:: Yang L, Kim TW, Han Y, et al. SARS-CoV-2 infection causes dopaminergic neuron senescence. Cell Stem Cell. 2024;31(2):196–211.e6. (Yang et al. 2024) DOI:: 10.1016/j.stem.2023.12.012 Study Design:: Human iPSC-derived DA neurons + postmortem substantia nigra tissue Sample Size:: n=13 acute COVID-19 postmortem, 8 controls Key Findings::
- SARS-CoV-2 directly infects DA neurons via ACE2
- Induces senescence (not acute cell death)
- Detectable viral transcripts in SN of COVID-19 postmortemLimitations:: Elderly sample (mean 69.7); acute COVID not long COVID; some with dementia/Parkinson’s; small n ME/CFS Relevance:: Key mechanistic precedent for DA neuron vulnerability to SARS-CoV-2. Suggests viral persistence/dormancy may drive chronic DA dysfunction. Certainty Assessment:: - Quality: High (Cell Stem Cell, direct mechanistic evidence) - Sample: Small (n=13 postmortem) - Relevance to LC/ME: Indirect (acute COVID, not long COVID, elderly, comorbid) - Score: 0.65
7 Rudroff 2024 — Basal Ganglia Fatigue Circuit in Long COVID
Full Citation:: Rudroff T. Decoding Post-Viral Fatigue: The Basal Ganglia’s Complex Role in Long-COVID. Neurology International. 2024;16(2):380–393. (Rudroff 2024) DOI:: 10.3390/neurolint16020028 Key Findings:: Narrative review + FDG-PET data showing reduced frontal-striatal glucose metabolism in long COVID. Basal ganglia fatigue circuit model. ME/CFS Relevance:: Integrates motor, cognitive, and motivational domains in common circuit. Convergent with Walitt 2024 finding of altered effort preference. Certainty Assessment:: - Quality: Low-medium (narrative review, limited original data) - Score: 0.50
8 Sauve et al. 2023 — GnRH Neuron Death in Long COVID (Precedent)
Full Citation:: Sauve F, Nampoothiri S, Clarke SA, et al. Long-COVID cognitive impairments and reproductive hormone deficits in men may stem from GnRH neuronal death. eBioMedicine. 2023;96:104784. (Sauve et al. 2023) DOI:: 10.1016/j.ebiom.2023.104784 Key Findings:: Postmortem study showing GnRH neuron death in hypothalamus of male long COVID patients. Establishes precedent for viral-induced specific neuronal subtype loss. ME/CFS Relevance:: Same general mechanism (infection → neuron subtype loss) may apply to DA neurons. Different cell type, shared principle. Certainty Assessment:: - Quality: Medium-high (postmortem, Netherlands Brain Bank) - Score: 0.65
9 Bantle et al. 2019 — Alphavirus Selective DA Neuron Loss (Animal Model)
Full Citation:: Bantle CM, Phillips AT, Smeyne RJ, et al. Infection with mosquito-borne alphavirus induces selective loss of dopaminergic neurons, neuroinflammation and widespread protein aggregation. NPJ Parkinson’s Disease. 2019;5:20. (Bantle et al. 2019) DOI:: 10.1038/s41531-019-0090-8 Key Findings:: Mouse model: WEEV causes selective DA neuron loss in SN. Demonstrates viral selectivity for DA neurons across virus families. ME/CFS Relevance:: Supports postviral DA vulnerability as general mechanism, not specific to SARS-CoV-2. Certainty Assessment:: - Quality: Medium (animal model only) - Score: 0.50
10 Chen et al. 2020 — ACE2 Distribution in Human Brain
Full Citation:: Chen R, Wang K, Yu J, et al. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains. Frontiers in Neurology. 2020;11:573095. (Chen et al. 2020) DOI:: 10.3389/fneur.2020.573095 Key Findings:: ACE2 highly expressed in SN and VTA (dopaminergic cell body regions). Establishes molecular basis for SARS-CoV-2 tropism to DA neurons. ME/CFS Relevance:: If ME/CFS shares postviral mechanisms, ACE2 expression in DA regions is relevant even without SARS-CoV-2 — similar receptors may exist for other viruses. Certainty Assessment:: - Quality: Medium - Replication: Supported by Hernández 2021 (rat brain) - Score: 0.60
11 Capuron et al. 2012 — Inflammation-Induced DA Deficiency Model
Full Citation:: Capuron L, Pagnoni G, Drake DF, et al. Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Archives of General Psychiatry. 2012;69(10):1044–1053. (Capuron et al. 2012) DOI:: 10.1001/archgenpsychiatry.2011.2094 Key Findings:: [18F]DOPA PET shows interferon-alpha reduces DA synthesis in basal ganglia, linked to anhedonia and psychomotor slowing. Establishes mechanistic chain: inflammation → DA deficiency → motivational/motor symptoms in humans. ME/CFS Relevance:: Foundational precedent for inflammation-driven DA dysfunction producing identical symptoms to ME/CFS (apathy, motor slowing). Cytokine model directly applicable to ME/CFS neuroinflammatory hypothesis. Certainty Assessment:: - Quality: High (Arch Gen Psychiatry, PET methodology, controlled cytokine challenge) - Score: 0.68
12 Mancini et al. 2023 — Dopamine Imbalance in Neuroinflammation Post-COVID
Full Citation:: Mancini M, Natoli S, Gardoni F, Di Luca M, Pisani A. Dopamine Transmission Imbalance in Neuroinflammation: Perspectives on Long-Term COVID-19. Int J Mol Sci. 2023;24(6):5618. (Mancini et al. 2023) DOI:: 10.3390/ijms24065618 Study Design:: Narrative review Key Findings::
- Proinflammatory cytokines, chemokines, and ROS disrupt DA homeostasis
- SARS-CoV-2-mediated neuroinflammation may impair nigrostriatal DAergic function
- Links neuroinflammation to α-synuclein pathology in DA neuronsME/CFS Relevance:: Provides mechanistic bridge from the gliosis observed in Braga 2023/2025 to the DA terminal loss seen in Liu 2026. Certainty Assessment:: - Quality: Medium (review, no original data) - Score: 0.55; discounted 0.47 (population weight 0.85, LC cohort)
13 Meyer et al. 2022 — PET/SPECT Brain Imaging Systematic Review in COVID-19
Full Citation:: Meyer PT, Hellwig S, Blazhenets G, Hosp JA. Molecular Imaging Findings on Acute and Long-Term Effects of COVID-19 on the Brain: A Systematic Review. J Nucl Med. 2022;63(7):971–980. (Meyer et al. 2022) DOI:: 10.2967/jnumed.121.263085 Key Findings::
- Reversible frontoparietal hypometabolism in acute COVID-19
- Controversial findings in post-COVID syndrome: some studies show limbic/subcortical hypometabolism, others null
- Nigrostriatal integrity loss noted in sporadic post-COVID parkinsonism cases
- Critical methodological appraisal of imaging heterogeneityME/CFS Relevance:: Documents the imaging controversy that Liu 2026 resolves with direct VMAT2 measurement. Certainty Assessment:: - Quality: High (J Nucl Med, systematic review, methodological critique) - Score: 0.65
14 Lee et al. 2021 — TGF-β1 Induces Central Fatigue and Suppresses Striatal Dopamine
Full Citation:: Lee WK, Kim Y, Jang H, et al. Exogenous Transforming Growth Factor-β in Brain-Induced Symptoms of Central Fatigue and Suppressed Dopamine Production in Mice. Int J Mol Sci. 2021;22(5):2580. (Lee et al. 2021) DOI:: 10.3390/ijms22052580 Study Design:: Animal model (C57BL/6 mouse) Key Findings::
- ICV TGF-β1 injection induced fatigue-like behaviors (FST immobility ↑, rotarod retention ↓, pain hypersensitivity, passive avoidance ↓)
- TGF-β1 suppressed tyrosine hydroxylase in VTA with striatal dopamine reduction
- TH suppression confirmed in SH-SY5Y human neuroblastoma cellsME/CFS Relevance:: Reactive astrocytes release TGF-β; this provides direct causal evidence that gliosis → TGF-β → TH suppression → DA deficiency. Complements the gliosis findings in Braga 2023/2025. Certainty Assessment:: - Quality: Medium (animal model, mechanistic) - Score: 0.50
15 Song et al. 2021 — Myelophil Restores Striatal Dopamine in Reserpine-Induced ME/CFS Model
Full Citation:: Song JH, Won SK, Eom GH, et al. Improvement Effects of Myelophil on Symptoms of Chronic Fatigue Syndrome in a Reserpine-Induced Mouse Model. Int J Mol Sci. 2021;22(19):10199. (Song et al. 2021) DOI:: 10.3390/ijms221910199 Study Design:: Animal model (reserpine-induced ME/CFS mouse) Key Findings::
- Reserpine (VMAT2 inhibitor) produced depression, pain, and fatigue behaviors
- Myelophil restored striatal dopamine + serotonin, increased TH expression
- Reduced neuroinflammation (Iba1) and normalized TGF-β in brainME/CFS Relevance:: Reserpine is a direct VMAT2 blocker — the same transporter measured by Liu 2026. Demonstrates pharmacological reversibility of VMAT2 impairment → reduced DA → fatigue. Direct animal-model parallel to the human VMAT2 PET finding. Certainty Assessment:: - Quality: Medium (animal model) - Score: 0.45
16 Chang et al. 2024 — Spike Protein Causes α-Synuclein Aggregation in DA Neurons
Full Citation:: Chang MH, Park JH, Lee HK, Choi JY, Koh YH. SARS-CoV-2 Spike Protein 1 Causes Aggregation of α-Synuclein via Microglia-Induced Inflammation and Production of Mitochondrial ROS. Biomedicines. 2024;12(6):1223. (Chang et al. 2024) DOI:: 10.3390/biomedicines12061223 Key Findings::
- S1 spike protein induced α-synuclein aggregation in BE(2)M-17 DA neurons via BV-2 microglial inflammation
- Spike + low-dose MPP+ synergistically boosted α-synuclein aggregation
- Metformin suppressed S1-induced inflammation and α-synucleinopathyME/CFS Relevance:: Links spike protein directly to DA neuron pathology. Suggests persistent spike protein (or viral reservoir) could drive ongoing α-synuclein aggregation → DA terminal vulnerability. Certainty Assessment:: - Quality: Medium (in vitro + rodent) - Score: 0.50
17 Pokharel et al. 2025 — SARS-CoV-2 Invades Substantia Nigra, Alters miR-330-5p
Full Citation:: Pokharel BR, Majumdar N, Williams F, et al. SARS-CoV-2 Infection of Substantia Nigra Pars Compacta Induces Expression of miR-330-5p at 10 Days Post-Infection. J Gen Virol. 2025;106(9):002149. (Pokharel et al. 2025) DOI:: 10.1099/jgv.0.002149 Key Findings::
- SARS-CoV-2 detected in SNpc at 10d post intranasal inoculation in K18-hACE2 mice
- Increased IL-1β, B1R, ADAM17; miR-330-5p significantly reduced
- ADAM17 confirmed as direct miR-330-5p target (luciferase assay)
- First direct evidence of SARS-CoV-2 tropism for dopaminergic cell body regionME/CFS Relevance:: Demonstrates SARS-CoV-2 can reach the substantia nigra where DA cell bodies reside. miR-330-5p/ADAM17 axis may be a molecular pathway for post-infection DA neuron vulnerability. Certainty Assessment:: - Quality: Medium (animal model, J Gen Virol) - Score: 0.55
18 Chatterjee et al. 2024 — SARS-CoV-2 + MPTP Synergy in SN Neurodegeneration
Full Citation:: Chatterjee D, Kurup D, Smeyne RJ. Environmental Exposures and Familial Background Alter the Induction of Neuropathology and Inflammation after SARS-CoV-2 Infection. bioRxiv (updated in NPJ Parkinsons Dis. 2025). 2024. (Chatterjee, Kurup, and Smeyne 2024) DOI:: 10.1038/s41531-025-00925-0 Key Findings::
- SARS-CoV-2 synergized with subtoxic MPTP to induce SN neurodegeneration
- Effect rescued by vaccination in WT mice but not in G2019S LRRK2 mutants (mRNA vaccine)
- Gene-environment-virus interaction: infection alone insufficient; primes for toxic "second hit"ME/CFS Relevance:: Explains why only some long COVID patients lose VMAT2 terminals — genetic background (e.g., LRRK2 variants) and environmental co-exposures may determine vulnerability. Relevant to ME/CFS heterogeneity. Certainty Assessment:: - Quality: Medium (animal model, preprint updated to journal) - Score: 0.45
19 Inderyas et al. 2026 — Dopaminergic FC Disruption in ME/CFS and Long COVID (7T fMRI)
Full Citation:: Inderyas M, Thapaliya K, Marshall-Gradisnik S, Barnden L. Distinct Functional Connectivity Patterns in Myalgic Encephalomyelitis and Long COVID Patients During Cognitive Fatigue: A 7 Tesla Task-fMRI Study. J Transl Med. 2026;24(1):236. (Inderyas et al. 2026) DOI:: 10.1186/s12967-026-07708-y Study Design:: 7T task-fMRI (Stroop), cross-sectional Sample Size:: n=32 ME/CFS, n=19 LC, n=27 HC Key Findings::
- Reduced FC between nucleus accumbens (DA hub) and vermis in LC vs HC
- Reduced dopaminergic hippocampal-N.Acc. connectivity implies blunted motivation/cognition
- Caudate and amygdala FC correlated with cognitive symptom scoresME/CFS Relevance:: First 7T fMRI evidence of dopaminergic circuit dysfunction in both ME/CFS and LC. Complements Liu 2026 structural VMAT2 finding with functional connectivity evidence. Direct ME/CFS cohort. Certainty Assessment:: - Quality: Medium-high (7T fMRI, adequate n, both ME/CFS and LC) - Score: 0.60
20 Taenzer et al. 2023 — Urine Metabolomics: DA Synthesis Disturbance in LC and ME/CFS
Full Citation:: Taenzer M, Löffler-Ragg J, Schroll A, et al. Urine Metabolite Analysis to Identify Pathomechanisms of Long COVID: A Pilot Study. Int J Tryptophan Res. 2023;16:11786469231220781. (Taenzer et al. 2023) DOI:: 10.1177/11786469231220781 Study Design:: Cross-sectional urine metabolomics pilot Sample Size:: n=25 LC, n=8 ME/CFS, n=8 HC Key Findings::
- Phenylalanine significantly lower in both LC and ME/CFS
- Dopamine and serotonin pathway metabolites deviated from reference ranges in many LC patients
- Fatigue associated with lower kynurenine, phenylalanine, and reduced Kyn/Trp ratioME/CFS Relevance:: Peripheral evidence of disturbed neurotransmitter precursor metabolism in both LC and ME/CFS — consistent with reduced DA synthesis capacity. Complements central (CSF) catecholamine findings from Aregawi 2026. Certainty Assessment:: - Quality: Low-medium (pilot, n=8 ME/CFS, urine not CSF) - Score: 0.50
21 Klempner 2001 — Two Controlled Trials of Antibiotic Treatment in Persistent Lyme Disease
Full Citation:: Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. New England Journal of Medicine. 2001;345(2):85–92. (Klempner et al. 2001) DOI:: 10.1056/NEJM200107123450202 Key Findings:: Two RCTs (n=78 seropositive, n=51 seronegative) testing 30d IV ceftriaxone + 60d oral doxycycline vs placebo in patients with persistent symptoms post-Lyme treatment. No significant difference between groups, but patients had been ill avg 4.7 years with 3+ prior antibiotic courses — heavily pre-treated population with potentially irreversible pathology. Conclusion:: Landmark negative trial that shaped IDSA guidelines against retreatment, but selection of chronic, heavily pre-treated patients limits generalizability to earlier-stage disease. Limitations:: Selection bias toward chronic refractory patients; underpowered (stopped early); 90-day treatment may be insufficient; did not address co-infections.
22 Fallon 2008 — IV Ceftriaxone for Lyme Encephalopathy
Full Citation:: Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. 2008;70(13):992–1003. (Fallon et al. 2008) DOI:: 10.1212/01.WNL.0000284604.61160.2d Key Findings:: 37 patients, 10 weeks IV ceftriaxone vs placebo. Cognitive improvement favored antibiotic at week 12, but not sustained to week 24 (relapse after discontinuation). Pain and physical functioning improvement in severely affected patients was sustained. Conclusion:: Short-term antibiotic retreatment produces temporary cognitive improvement, but relapse after discontinuation suggests need for longer treatment. Limitations:: Small sample (n=37); 10-week treatment may be insufficient; relapse at 24 weeks off-drug.
23 Krupp 2003 — STOP-LD Trial
Full Citation:: Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology. 2003;60(12):1923–1930. (Krupp et al. 2003) DOI:: 10.1212/01.WNL.0000071227.23769.9e Key Findings:: 55 patients, 28d IV ceftriaxone vs placebo. Fatigue improved significantly (rate ratio 3.5, p=0.001). Cognitive function did not improve. Conclusion:: Short-term ceftriaxone improved fatigue but not cognition; insufficient to recommend retreatment in post-Lyme syndrome. Limitations:: Single center; 28-day treatment may be insufficient; small sample; fatigue-only positive outcome.
24 DeLong 2012 — Biostatistical Review of Lyme Retreatment Trials
Full Citation:: DeLong AK, Blossom B, Maloney EL, Phillips SE. Antibiotic retreatment of Lyme disease in patients with persistent symptoms: a biostatistical review of randomized, placebo-controlled, clinical trials. Contemporary Clinical Trials. 2012;33(6):1132–1142. (DeLong et al. 2012) DOI:: 10.1016/j.cct.2012.08.009 Key Findings:: Systematic biostatistical review of all 4 RCTs on antibiotic retreatment for persistent Lyme. Klempner trials were underpowered with inefficient methods. Krupp found significant fatigue improvement. Fallon found cognitive improvement at 12 weeks. Treatment effects consistent with continued infection; not refuted by any adequately powered trial. Conclusion:: Negative Lyme retreatment trials were methodologically flawed and underpowered; positive findings from Krupp and Fallon suggest retreatment can be beneficial. Limitations:: Re-analysis of existing trials, not new data; cannot prove treatment-duration hypothesis directly.
25 Cameron 2006 — Generalizability Critique of Klempner Trials
Full Citation:: Cameron DJ. Generalizability in two clinical trials of Lyme disease. Epidemiologic Perspectives & Innovations. 2006;3:12. (Cameron 2006) DOI:: 10.1186/1742-5573-3-12 Key Findings:: Epidemiologic review showing Klempner trials enrolled patients ill avg 4.7 years with 3+ prior antibiotic courses. These selection factors make trials non-generalizable. NIH press release and IDSA guidelines over-extrapolated these negative results. Conclusion:: Klempner trials’ negative outcome likely reflects selection of treatment-refractory patients, not evidence against antibiotic efficacy in less chronic disease. Limitations:: Re-analysis only; no original data; author is ILADS-affiliated clinician.
26 Feng 2019 — Borrelia Persister/Biofilm in Mouse Model
Full Citation:: Feng J, Li T, Yee R, et al. Stationary phase persister/biofilm microcolony of Borrelia burgdorferi causes more severe disease in a mouse model of Lyme arthritis. Discovery Medicine. 2019;27(148):125–138. (Feng et al. 2019) DOI:: n/a (PMID: 30946803) Key Findings:: B. burgdorferi biofilm-like microcolonies are more antibiotic-tolerant than log-phase spirochetes. Murine infection with microcolonies could not be eradicated by doxycycline, ceftriaxone, or vancomycin monotherapy, but was eradicated by daptomycin+doxycycline+ceftriaxone combination. Provides mechanistic basis for why standard antibiotic durations fail. Conclusion:: Borrelia persister forms require combination therapy, not monotherapy; standard short-term monotherapy cannot eradicate all morphological variants. Limitations:: Animal model only; in vitro findings may not fully translate to human disease.
27 Montoya 2013 — Valganciclovir RCT for CFS
Full Citation:: Montoya JG, Kogelnik AM, Bhangoo M, et al. Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome. Journal of Medical Virology. 2013;85(12):2101–2109. (Montoya et al. 2013) DOI:: 10.1002/jmv.23713 Key Findings:: 30 CFS patients with elevated HHV-6/EBV IgG, 6 months valganciclovir vs placebo. Primary outcome (MFI-20) not statistically significant, but secondary outcomes significant (mental fatigue, FSS, cognitive function). Responder rate 7.4x higher in valganciclovir arm. Authors called for larger trials with longer treatment. Conclusion:: Valganciclovir may benefit a subset, but trial underpowered (n=30) with only 6 months treatment. Limitations:: Small sample; primary outcome missed significance; 6-month treatment may be insufficient; selected population.
28 Watt 2012 — Valganciclovir Response in CFS: Duration Matters
Full Citation:: Watt T, Oberfoell S, Balise R, et al. Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers. Journal of Medical Virology. 2012;84(12):1967–1974. (Watt et al. 2012) DOI:: 10.1002/jmv.23411 Key Findings:: Retrospective review of 61 CFS patients on valganciclovir. 52% responded. Longer treatment duration significantly correlated with improved response (p=0.0002). Mean improvement: +19% physical, +23% cognitive. Conclusion:: Treatment duration is a critical variable in antiviral response for CFS; longer treatment yields better outcomes. Limitations:: Uncontrolled, unblinded, retrospective; no placebo group.
29 Fluge 2015 — Rituximab Phase II: Delayed Response Pattern
Full Citation:: Fluge Ø, Risa K, Lunde S, et al. B-Lymphocyte depletion in Myalgic Encephalopathy/Chronic Fatigue Syndrome. An open-label Phase II study with rituximab maintenance treatment. PLoS ONE. 2015;10(7):e0129898. (Fluge et al. 2015) DOI:: 10.1371/journal.pone.0129898 Key Findings:: 29 ME/CFS patients, open-label rituximab with maintenance over 15 months. 64% responded. Mean lag from first infusion to response: 23 weeks (range 8–66). B-cell regeneration preceded relapse. Conclusion:: Prolonged B-cell depletion produced sustained responses in a subgroup, but response lag (23 weeks mean) means short trials would miss the effect entirely. Limitations:: Open-label; no placebo; small sample; delayed response = short trials would produce false negatives.
30 Fluge 2019 — Rituximab Phase III (RituxME): Negative Result
Full Citation:: Fluge Ø, Rekeland IG, Lien K, et al. B-Lymphocyte depletion in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 2019;170(9):585–593. (Fluge et al. 2019) DOI:: 10.7326/M18-1451 Key Findings:: 151 ME/CFS patients, double-blind Phase III. Rituximab with maintenance over 12 months vs placebo. No difference in primary or secondary outcomes. Response rate: 26% rituximab vs 35.1% placebo. Cyclophosphamide subgroup may differ. Conclusion:: Definitive negative trial contradicting Phase II. Failed to confirm rituximab efficacy. High placebo response. Limitations:: Possible placebo confound; the B-cell hypothesis as tested by rituximab was not supported; 12-month treatment may still be insufficient for certain immunological targets.
31 Strayer 2020 — Rintatolimod: Disease Duration as Effect Modifier
Full Citation:: Strayer DR, Young D, Mitchell WM. Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. PLoS ONE. 2020;15(10):e0240403. (Strayer, Young, and Mitchell 2020) DOI:: 10.1371/journal.pone.0240403 Key Findings:: Post-hoc analysis of Phase III rintatolimod trial (n=208). Patients with disease duration 2–8 years showed 2x improvement vs full population. Less than 2 or more than 8 years disease: no response. 51.2% of 2–8 year subset improved exercise by %. Conclusion:: Disease duration at treatment initiation is critical. Trials not stratifying by duration may miss treatment effects. Limitations:: Post-hoc analysis; manufacturer-sponsored; needs prospective validation.
32 Smith 2015 — NIH Systematic Review: Trials Limited by Duration
Full Citation:: Smith ME, Haney E, McDonagh M, et al. Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A systematic review for a National Institutes of Health Pathways to Prevention Workshop. Annals of Internal Medicine. 2015;162(12):841–850. @[“Smith2015ME/CFSTxSysRev”] DOI:: 10.7326/M15-0114 Key Findings:: Systematic review of 35 ME/CFS treatment trials. Rintatolimod improved exercise (low strength). All other pharmacological treatments inconclusive. Trials limited by size, duration, applicability, and methodological quality. Conclusion:: Evidence base insufficient. More definitive studies with adequate size, duration, and subgroup analysis needed. Limitations:: Identifies duration as a limitation of most trials, supporting the treatment-duration critique.
33 Popov 2026 — Tick-Borne Co-Infection: Beyond Standard Lyme Treatment
Full Citation:: Popov G, Bashchobanov D, Andonova R. Tick-borne co-infection in Lyme disease: Clinical impact, diagnostic challenges, and therapeutic perspectives. Microorganisms. 2026;14(2):325. (Popov, Bashchobanov, and Andonova 2026) DOI:: 10.3390/microorganisms14020325 Key Findings:: Comprehensive review of tick-borne co-infections. Co-infections increase severity, prolong symptoms. Standard Lyme antibiotics do not cover protozoan (Babesia) or viral agents. Pathogen-specific combination therapy required. Conclusion:: Monotherapy for Lyme is insufficient when co-infections present. Trials not screening/treating co-infections may produce false-negative results. Limitations:: Narrative review; no original data; recommendations from clinical experience not RCTs.
34 Horowitz 2020 — Dapsone Combination for Chronic Lyme/PTLDS
Full Citation:: Horowitz RI, Freeman PR. Efficacy of double-dose dapsone combination therapy in the treatment of chronic Lyme disease/post-treatment Lyme disease syndrome (PTLDS) and associated co-infections. Antibiotics. 2020;9(11):725. (Horowitz and Freeman 2020) DOI:: 10.3390/antibiotics9110725 Key Findings:: Case series (n=3) + retrospective chart review (n=40). Double-dose dapsone combination for chronic Lyme. 98% reported symptom improvement; 45% remission >=1 year. Patients had failed standard protocols. Conclusion:: Combination therapy targeting persistent Borrelia + co-infections may succeed where monotherapy fails. Limitations:: Uncontrolled retrospective design; small; Horowitz is ILADS-affiliated.
35 Rogerson 2020 — Lyme Patient Outcomes: IDSA vs ILADS Guidelines
Full Citation:: Rogerson AG, Lloyd VK. Lyme disease patient outcomes and experiences: A retrospective cohort study. Healthcare. 2020;8(3):322. (Rogerson and Lloyd 2020) DOI:: 10.3390/healthcare8030322 Key Findings:: 210 Canadian Lyme patients treated per ILADS guidelines (longer duration, combination approaches). Majority responded with significant symptom decrease (p \(<\) 0.05). ILADS-guided care produced better outcomes than IDSA short-course recommendations. Conclusion:: Longer treatment duration and co-infection management associated with positive outcomes in real-world cohort. Limitations:: Retrospective; no control; single clinic; referral bias.
36 Girgis 2025 — Aberrant T-Cell Phenotypes in PTLDS
Full Citation:: Girgis AA, Cimbro R, Yang T, Rebman AW, Sewell T, Villegas de Flores D, Vadalia A, Robinson WH, Cox AL, Darrah E, Soloski MJ, Aucott J. Aberrant T-cell phenotypes in a cohort of patients with post-treatment Lyme disease. Frontiers in Immunology. 2025;16:1607619. (Girgis et al. 2025) DOI:: 10.3389/fimmu.2025.1607619 PMID:: 40703523 Study Design:: Cross-sectional immunophenotyping (19-parameter flow cytometry + cytokine profiling) Sample Size:: n=272 PTLD, n=28 healthy controls Key Findings::
- Fewer CXCR5+ CD4+ naïve T cells in PTLD vs HC (5.2% vs 8.3%, Padj $<$ 0.001)
- Increased CXCR3+CCR4-CCR6- CD8 T cells (43.1% vs 25.7%, Padj $<$ 0.01)
- Elastic net classifier AUC 0.83
- Female-specific central memory CD8 expansion in high-fatigue subgroup
- Symptom-domain linking: musculoskeletal pain associated with CXCR5+CD4+ abundanceConclusion:: PTLDS is characterized by aberrant T-cell homeostasis with symptom-domain-specific immune correlates; first detailed immunophenotyping in PTLDS. ME/CFS Relevance:: Directly comparable to ME/CFS immunophenotyping studies; supports shared immune dysregulation mechanisms. Symptom-domain linking approach parallels ME/CFS subgroup analyses. Limitations:: Cross-sectional; no ME/CFS comparator arm; Hopkins cohort may not generalize.
37 Yakubovsky 2026 — Cat Scratch Disease Encephalitis: Long-Term Outcomes
Full Citation:: Yakubovsky M, Kadar L, Katchman E, Regev A, Atamna A, Yelin D, Paul M, Finn T, Cohen R, Yahav D, Megged O, Chazan B, Gottesman G, Moran-Gilad J, Zimhony O, Grisaru-Soen G, Paran Y, Ben-Ami R, Gadoth A, Aizenstein O, Ephros M, Gurevich T, Giladi M. Cat scratch disease encephalitis: New insights into rate, clinical features, and long-term outcomes. International Journal of Infectious Diseases. 2026;164:108395. (Yakubovsky et al. 2026) DOI:: 10.1016/j.ijid.2026.108395 PMID:: 41544843 Study Design:: National retrospective cohort (Israeli CSD surveillance) Key Findings:: Largest systematic description of B. henselae encephalitis. Neurological involvement with measurable long-term cognitive deficits. Recovery trajectory prolonged. Conclusion:: Bartonella CNS infection produces persistent cognitive sequelae independent of prior ME/CFS diagnosis. ME/CFS Relevance:: Demonstrates Bartonella neuroinvasion as a potential mechanism for cognitive dysfunction in tick-exposed ME/CFS patients. Independent from Breitschwerdt chronic fatigue data. Limitations:: Retrospective; B. henselae only; CSD cases only (not chronic Bartonella); no ME/CFS comparator.
38 Guirguis 2024 — Bartonella in Mild Cognitive Impairment (Pilot)
Full Citation:: Guirguis V, Pupillo F, Rodrigues S, Walker N, Roth H, Liedig CE, Maggi RG, Breitschwerdt EB, Frohlich F. Bartonella spp. infection in people with Mild Cognitive Impairment: A pilot study. PLoS One. 2024;19(8):e0307060. (Guirguis et al. 2024) DOI:: 10.1371/journal.pone.0307060 PMID:: 39172940 Study Design:: Pilot cross-sectional Sample Size:: n=16 MCI, n=30 controls Key Findings:: Higher Bartonella spp. DNA detection in MCI patients than controls. Suggests Bartonella may contribute to cognitive decline. Conclusion:: Extends Bartonella cognitive involvement beyond ME/CFS into broader cognitive impairment. Limitations:: Very small pilot; unblinded; low statistical power. Low certainty.
39 Bush 2024 — Neurobartonelloses
Full Citation:: Bush JC, Robveille C, Maggi RG, Breitschwerdt EB. Neurobartonelloses: emerging from obscurity! Parasites & Vectors. 2024;17(1):416. (Bush et al. 2024) DOI:: 10.1186/s13071-024-06491-3 PMID:: 39369199 Study Design:: Comprehensive review Key Findings::
- Bartonella species are established neurotropic pathogens
- Neurological spectrum: cognitive impairment, neuropsychiatric, neuropathy, movement disorders
- Serology insensitive; enrichment culture/PCR preferred for diagnosis
- Proposes "neurobartonelloses" as distinct clinical entityConclusion:: Bartonella causes a broad spectrum of neurological disease that is underdiagnosed due to insensitive serology. ME/CFS Relevance:: Provides neurological framework for understanding Bartonella as a driver of CNS symptoms in tick-exposed ME/CFS patients. Complements ch07 coverage. Limitations:: Review; some claims extrapolated from animal models; Breitschwerdt group perspective.
40 Marques 2026 — PTLDS Epitope Profiling
Full Citation:: Marques AR, Sanchez-Vicente S, Nagapurkar A, Eschman A, Ng SP, Lipkin WI, Tokarz R. Evaluation of immunoreactive epitopes in the sera and cerebrospinal fluid of patients with post-treatment Lyme disease syndrome. Scientific Reports. 2026;16(1):10389. (Marques et al. 2026) DOI:: 10.1038/s41598-026-42941-x PMID:: 41826406 Study Design:: Cross-sectional epitope profiling Key Findings::
- Identified immunoreactive epitopes differentiating PTLDS from resolved Lyme
- Paired CSF-serum analysis provides CNS-compartment immune window
- Potential epitope-based biomarker for objective PTLDS diagnosisConclusion:: Epitope profiling offers a novel diagnostic approach for PTLDS that may improve upon standard two-tier serology. ME/CFS Relevance:: If validated, could help identify tick-borne infection as etiological driver in ME/CFS subgroups. Parallel to ME/CFS epitope-based biomarker development. Limitations:: Cross-sectional; replication needed; preprint at time of analysis.
41 Nawrocki 2025 — CDC: Nonspecific Symptoms After Lyme Disease
Full Citation:: Nawrocki CC, Delorey MJ, Earley AR, Hook SA, Kugeler KJ, Marx GE, Mead PS, Hinckley AF. Nonspecific Symptoms Attributable to Lyme Disease in High-Incidence Areas, United States, 2017-2021. Emerging Infectious Diseases. 2025;31(14):30-37. (Nawrocki et al. 2025) DOI:: 10.3201/eid3114.250459 PMID:: 41570190 Study Design:: Retrospective claims cohort Sample Size:: n=24,503 LD cases, n=122,095 matched controls Key Findings::
- Pain/fatigue/cognitive codes 5.0% more frequent in LD vs controls
- Symptom codes comprised ~11% of total codes in LD patients
- Symptoms declined at 6-12 months
- Fatigue specifically persisted beyond 12 months (only domain not normalizing)Conclusion:: Absolute risk of persistent post-Lyme symptoms may be lower than 10-20% in general LD population, but fatigue is the most persistent domain. ME/CFS Relevance:: Largest population-level estimate of post-Lyme symptom burden. Fatigue persistence mirrors ME/CFS. Suggests PTLDS prevalence estimates require domain-specific stratification. Limitations:: Claims-based (ICD codes, not validated questionnaires); may undercount mild symptoms; no ME/CFS comparator.
42 Georgopoulos 2025 — HLA Bridge: ME/CFS, PTLDS, Long COVID
Full Citation:: Georgopoulos AP, James LM, Peterson PK. HLA and pathogens in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and other post-infection conditions. Scientific Reports. 2025;15:37303. (Georgopoulos, James, and Peterson 2025) DOI:: 10.1038/s41598-025-21230-z PMID:: 41136524 Study Design:: In silico HLA binding affinity prediction Key Findings::
- ME/CFS susceptibility HLA alleles weakly bind Borrelia burgdorferi antigens
- ME/CFS protective HLA alleles strongly bind Borrelia antigens
- Same pattern for HHV and SARS-CoV-2 antigens
- Unifying mechanism: weak HLA-antigen binding → persistent antigens → chronic illnessConclusion:: Shared HLA-mediated vulnerability across ME/CFS, PTLDS, and Long COVID suggests common mechanism of persistent antigen-driven pathology. ME/CFS Relevance:: Direct mechanistic hypothesis for why tick-borne infection triggers ME/CFS in genetically susceptible individuals. Bridges the three post-infectious syndromes. Limitations:: In silico only; small number of HLA alleles; binding affinity does not guarantee functional outcome; requires wet-lab validation.
43 Milovanovic 2025 — Autonomic Comparison: Late-Stage Lyme vs CFS vs Post-COVID
Full Citation:: Milovanovic B, Markovic N, Petrovic M, Stojanovic S, Zugic V, Ostojic M, Bojic M. The Relationship Between Hemodynamic Responses During Head-Up Tilt Testing and Parameters of Infection in Post-COVID Syndrome, Chronic Fatigue Syndrome, and Late-Stage Lyme Disease. Viruses. 2025;17(11):1430. (Milovanovic et al. 2025) DOI:: 10.3390/v17111430 PMID:: 41305452 Study Design:: Cross-sectional HUT testing with infection parameter correlation Key Findings::
- All three groups (post-COVID, CFS, late-stage Lyme) show similar autonomic dysfunction
- Infection parameters correlate with hemodynamic responses
- Lyme and CFS groups show similar HUT patternsConclusion:: Shared dysautonomia mechanism across late-stage Lyme, CFS, and post-COVID with infection parameter correlation. ME/CFS Relevance:: Direct HUT comparison confirms that Lyme-associated dysautonomia matches ME/CFS pattern. Supports autonomic dysfunction as shared mechanism. Limitations:: Unclear diagnostic criteria for “late-stage Lyme”; single center; moderate sample size.
44 Nair 2025 — VlsE Antibody Differentiates Lyme Disease Stage
Full Citation:: Nair N, Marques A, Horn EJ, Brown G, Gomes-Solecki M. Class and isotype of VlsE-specific antibody differentiates Lyme disease stage. Journal of Clinical Microbiology. 2025;63(8):e0034725. (Nair et al. 2025) DOI:: 10.1128/jcm.00347-25 PMID:: 40662763 Study Design:: Cross-sectional diagnostic accuracy Key Findings:: VlsE antibody class/isotype differentiates early vs late vs post-treatment Lyme disease stages. Potential to distinguish active infection from past exposure. Conclusion:: VlsE isotyping may improve Lyme disease staging and help differentiate ongoing antigenic stimulation from resolved infection. ME/CFS Relevance:: If validated, could identify ME/CFS patients with ongoing Borrelia antigenic stimulation who might benefit from targeted treatment. Limitations:: Moderate sample size; needs validation in PTLDS/chronic Lyme controversy populations.
45 Kuvaldina 2025 — Disulfiram Pilot for Persistent Lyme
Full Citation:: Kuvaldina M, Preston J, McClellan D, Pavlicova M, Brannagan TH, Fallon BA. A pilot study of disulfiram for individuals with persistent symptoms despite prior antibiotic treatment for Lyme disease. Frontiers in Medicine. 2025;12:1549324. (Kuvaldina et al. 2025) DOI:: 10.3389/fmed.2025.1549324 PMID:: 40265182 Study Design:: Open-label pilot Sample Size:: n=15 Key Findings:: Some symptom improvement with disulfiram (anti-persister mechanism). Significant neuropathy adverse effects. Conclusion:: Disulfiram shows potential for persistent Lyme symptoms but tolerability concerns limit use. ME/CFS Relevance:: Novel treatment mechanism outside antibiotic framework. If persistent Borrelia drives some ME/CFS cases, antipersister agents may be relevant. Limitations:: Open-label; n=15; no control arm; high AE rate (neuropathy).
46 Adler 2024 — Dysautonomia Following Lyme Disease (Review)
Full Citation:: Adler BL, Chung T, Rowe PC, Aucott J. Dysautonomia following Lyme disease: a key component of post-treatment Lyme disease syndrome? Frontiers in Neurology. 2024;15:1344862. (Adler et al. 2024) DOI:: 10.3389/fneur.2024.1344862 PMID:: 38390594 Study Design:: Narrative review Key Findings:: Synthesizes evidence for Lyme-associated dysautonomia. Proposes PTLDS shares autonomic dysfunction mechanisms with PASC and ME/CFS. Identifies gaps. Conclusion:: Dysautonomia is a key but under-researched component of PTLDS that bridges to ME/CFS and long COVID. ME/CFS Relevance:: Supports ch36 coverage of shared autonomic dysfunction; provides Hopkins group perspective. Limitations:: Review; no original data; content largely covered in ch36.
47 Shor 2011 — Seronegative Chronic Lyme in Internationally-Defined CFS
Full Citation:: Shor S. Seronegative chronic Lyme disease in a large proportion of patients with internationally-defined chronic fatigue syndrome. IACFS/ME Biennial Conference, San Francisco, CA. 2011. (Shor 2011) DOI:: N/A (conference presentation) Study Design:: Single-author retrospective uncontrolled chart review Sample Size:: n=210 Key Findings::
- 209/210 (99%) patients with internationally-defined CFS classified as "seronegative chronic Lyme"
- Diagnostic criteria: ANY ONE of single WB band, co-infection serology, low CD57, elevated C4a, or elevated C6
- Claims 62-88% benefit from prolonged antimicrobial therapy
- No placebo control, no blinding, no objective outcome measuresConclusion:: Author concludes most CFS is actually seronegative Lyme and responds to prolonged antibiotics. Limitations:: Single-author, retrospective, uncontrolled, unblinded. Non-validated diagnostic criteria. Author is past president of ILADS (Lyme advocacy body). Highest-vs-lowest outcome comparison prone to regression-to-mean. Directly contradicted by multiple RCTs.
48 Feder 2007 — A Critical Appraisal of “Chronic Lyme Disease”
Full Citation:: Feder HM, Johnson BJB, O’Connell S, Shapiro ED, Steere AC, Wormser GP, Ad Hoc International Lyme Disease Group. A critical appraisal of “chronic Lyme disease”. New England Journal of Medicine. 2007;357(14):1422-1430. (Feder et al. 2007) DOI:: 10.1056/NEJMra072023 PMID:: 17914043 Study Design:: Multi-author expert review Key Findings::
- Rejects "chronic Lyme disease" as a valid diagnostic entity
- Distinguishes PTLDS from the non-validated "chronic Lyme" construct
- Documents that prolonged antibiotic therapy is unproven and causes harm
- Covers widespread serologic misinterpretation and non-validated testingConclusion:: “Chronic Lyme disease” is a misdiagnosis applied to patients with medically unexplained symptoms, not persistent Borrelia infection. Limitations:: Narrative review; author group includes notable Lyme experts. Inflammatory to some patients and alternative practitioners.
49 Lantos 2015 — Chronic Lyme Disease (Review)
Full Citation:: Lantos PM. Chronic Lyme disease. Infectious Disease Clinics of North America. 2015;29(2):325-340. (Lantos 2015) DOI:: 10.1016/j.idc.2015.02.006 PMID:: 25999227 Study Design:: Narrative review Key Findings::
- Chronic Lyme is a poorly defined diagnosis for prolonged unexplained symptoms
- No evidence for treatment-refractory persistent Borrelia infection
- Prolonged antibiotics do not prevent or ameliorate symptoms and cause harm
- Non-validated diagnostic tests (ELISPOT, CD57, C4a) lack specificityConclusion:: Chronic Lyme is not a valid infectious disease diagnosis. Limitations:: Single-author review; reflects mainstream infectious disease consensus.
50 Berende 2016 — PLEASE Trial: Longer-Term Antibiotics for Lyme Symptoms
Full Citation:: Berende A, ter Hofstede HJM, Vos FJ, van Middendorp H, Vogelaar ML, Tromp M, van den Hoogen FH, Donders ART, Evers AWM, Kullberg BJ. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. New England Journal of Medicine. 2016;374(13):1209-1220. (Berende et al. 2016) DOI:: 10.1056/NEJMoa1505425 PMID:: 27028911 Study Design:: Multicenter, double-blind, randomized, placebo-controlled trial Sample Size:: n=281 (280 in modified ITT) Key Findings::
- 2 weeks open-label IV ceftriaxone then 12 weeks doxycycline, clarithromycin+hydroxychloroquine, or placebo
- SF-36 PCS at week 14: no significant difference between groups (P=0.69)
- Mean PCS: doxycycline 35.0, clarithromycin+HCQ 35.6, placebo 34.8
- All groups improved from baseline (P\<0.001)
- No serious drug-related AEs in randomized phaseConclusion:: Longer-term antibiotic treatment did not improve quality of life beyond shorter-term treatment. Directly contradicts antibiotic-response claims. Limitations:: All patients received 2 weeks open-label ceftriaxone first (confounds interpretation of oral phase). Inclusion required positive Lyme serology or documented prior Lyme; not generalizable to “seronegative” populations.
51 Patrick 2015 — Lyme Diagnosed by Alternative Methods vs CFS
Full Citation:: Patrick DM, Miller RR, Gardy JL, Parker SM, Morshed MG, Steiner TS, Singer J, Shojania KG, Tang P, Complex Chronic Disease Study Group. Lyme disease diagnosed by alternative methods: a phenotype similar to that of chronic fatigue syndrome. Clinical Infectious Diseases. 2015;61(7):1084-1091. (Patrick et al. 2015) DOI:: 10.1093/cid/civ470 PMID:: 26054331 Study Design:: Prospective cohort comparison Sample Size:: n=81 (51 chronic Lyme by alternative diagnosis, 30 CFS) Key Findings::
- No objective laboratory evidence of active Borrelia infection in either group
- Phenotypes were essentially indistinguishable between groups
- "Chronic Lyme" patients diagnosed by alternative methods have CFS by another name
- Both groups had similarly elevated symptom burdenConclusion:: Chronic Lyme diagnosed by alternative methods is phenotypically identical to CFS. Limitations:: Moderate sample size; single Canadian centre.
52 Dattwyler 1988 — Seronegative Lyme Disease (Original Description)
Full Citation:: Dattwyler RJ, Volkman DJ, Luft BJ, Halperin JJ, Thomas J, Golightly MG. Seronegative Lyme disease: dissociation of specific T- and B-lymphocyte responses to Borrelia burgdorferi. New England Journal of Medicine. 1988;319(22):1441-1446. (Dattwyler et al. 1988) DOI:: 10.1056/NEJM198812013192203 PMID:: 3054554 Study Design:: Case-control immunology study Sample Size:: n=17 seronegative chronic Lyme, n=18 seropositive chronic Lyme, controls Key Findings::
- 17 patients with documented prior acute Lyme and oral antibiotics had absent antibodies by ELISA/IFA
- T-cell proliferative responses to B. burgdorferi were preserved (SI 17.8 vs 15.8 in seropositives)
- Establishes that seronegativity does not exclude Borrelia infection in patients with antecedent LymeConclusion:: Seronegative Lyme exists in patients with documented antecedent Lyme and early antibiotic treatment. Limitations:: n=17; pre-dates modern two-tier serologic testing; all patients had documented acute Lyme (not applicable to Shor’s CFS population without known antecedent Lyme).
53 Marzec 2017 — Serious Infections from Chronic Lyme Treatment (CDC/MMWR)
Full Citation:: Marzec NS, Nelson C, Waldron PR, Blackburn BG, Hosain S, Greenhow T, Green GM, Lomen-Hoerth C, Golden M, Mead PS. Serious bacterial infections acquired during treatment of patients given a diagnosis of chronic Lyme disease — United States. MMWR Morbidity and Mortality Weekly Report. 2017;66(23):607-609. (Marzec et al. 2017) DOI:: 10.15585/mmwr.mm6623a3 PMID:: 28617768 Study Design:: CDC MMWR case series (public health surveillance) Sample Size:: 5 cases Key Findings::
- Septic shock from contaminated IV lines
- Osteomyelitis
- C. difficile colitis
- Paraspinal abscess
- Documented fatal outcomes from prolonged IV antibiotics for "chronic Lyme"Conclusion:: Treatments for “chronic Lyme disease” carry serious, potentially fatal risks. No evidence of benefit justifies these harms. Limitations:: Case series (n=5), not population-level incidence. May underestimate prevalence as passive surveillance.